Biodesix Presents New Real-World Evidence on Nodify Lung Testing at CHEST 2026

LOUISVILLE, Colo., Oct. 13, 2026 /CourierPR/ -- Biodesix, a leading diagnostics solutions company, is set to present new real-world evidence supporting the integration of Nodify Lung® testing into routine lung nodule care at CHEST 2026. The presentations, which will take place on Tuesday, October 20, and Monday, October 19, will highlight how blood-based lung nodule risk assessment guides clinical decision-making and optimizes the use of imaging and other diagnostic procedures.

At CHEST 2026, Biodesix will present multiple studies that build upon the strong evidence base of Nodify Lung testing. The company has enrolled more than 2,000 patients who received Nodify Lung testing in routine clinical practice, as part of the CLARIFY study. This extensive patient pool provides a robust dataset for evaluating the effectiveness of Nodify Lung testing in various clinical scenarios.

On Tuesday, October 20, Biodesix will present three studies at the conference. This study compares the use of positron emission tomography (PET) imaging with blood-based biomarkers in managing pulmonary nodules, providing insights into the most effective diagnostic pathway.

This analysis aims to determine the optimal sequence of diagnostic tests to minimize unnecessary procedures and improve patient outcomes.

This study focuses on how proteomics risk stratification can help reduce patient loss to follow-up, ensuring that patients receive timely and appropriate care.

This presentation will explore how blood-based biomarkers can be integrated into structured care pathways to enhance clinical decision-making and patient adherence to follow-up.

Biodesix team members will also be available at booth #745 to discuss how blood-based and radiomic biomarkers can support a multimodal approach to lung nodule management and lung health diagnostics. The presentations at CHEST 2026 reflect the growing focus on real-world implementation of Nodify Lung testing, moving beyond the accuracy of blood-based biomarkers to their routine incorporation into structured care pathways.

Biodesix, Inc. is a leading diagnostics solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease.